+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Therapeutics Market - Global Forecast 2026-2032- Product Image
Anti-Obesity Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Anti-Obesity Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305474
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Obesity Therapeutics Market is projected to reach USD 12.67 Billion in 2026. It is expected to continue growing at a CAGR of 8.87%, reaching USD 21.21 Billion by 2032.

The anti-obesity therapeutics market is moving from adjunct lifestyle support to evidence-based chronic disease management. World Health Organization data show that adult obesity has more than doubled since 1990, with more than 1 billion people living with obesity globally in 2022, including 890 million adults and 159 million children and adolescents.

Commercial and clinical momentum is being driven by GLP-1 receptor agonists, dual GIP/GLP-1 agonists, cardiometabolic outcome evidence, and payer reassessment of obesity as a long-term medical condition. Clinical data from STEP and SURMOUNT trials, including weight reductions approaching 15% with semaglutide 2.4 mg and more than 20% with tirzepatide in selected trial populations, have reset expectations for obesity pharmacotherapy and intensified focus on durable outcomes, tolerability, and patient persistence.

Transformative Shifts in the Obesity Treatment Landscape

The landscape is being transformed by the shift from short-duration weight-loss products to chronic metabolic therapies that address obesity-related complications. Regulatory approvals of advanced incretin-based obesity medicines, along with expanding real-world use, have accelerated physician adoption, patient demand, and manufacturing scale-up across injectable obesity drugs.

A second major shift is the convergence of obesity care with cardiovascular, renal, hepatic, sleep, and diabetes management. The SELECT trial reported a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, strengthening the value proposition for payers and health systems. This evidence is pushing anti-obesity therapeutics beyond cosmetic weight reduction toward measurable cardiometabolic risk reduction.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing anti-obesity therapeutics across discovery, clinical development, commercialization, and patient support. AI-enabled molecular modeling, phenotyping, trial recruitment analytics, and safety signal detection are helping accelerate pipeline decisions for incretin-based drugs, oral peptides, amylin analogs, gut hormone combinations, and next-generation metabolic therapies.

In clinical practice, AI can support obesity risk stratification, adherence prediction, dose-titration workflows, and integrated monitoring of cardiometabolic markers such as glycemic control, blood pressure, lipid levels, and liver health indicators. The strongest near-term impact is expected in identifying patients likely to benefit, improving persistence, and supporting evidence generation from real-world data while maintaining privacy protection, bias control, explainability, and regulatory-grade validation.

Key Regional Insights

North America remains the most commercially advanced region due to high obesity prevalence, strong specialist networks, mature reimbursement infrastructure, and rapid uptake of GLP-1-based obesity pharmacotherapy. Europe is expanding through centralized regulatory pathways, national health technology assessments, and increasing recognition of obesity as a chronic disease, although access varies by country and budget impact concerns remain significant. Asia-Pacific is emerging as a major strategic region as China, India, Japan, South Korea, and Australia confront rising metabolic disease burdens, urban lifestyle changes, and expanding private healthcare demand.

Latin America shows meaningful medical need, led by Mexico and Brazil, where obesity and type 2 diabetes are major public health priorities and nutrition-related chronic disease policies are increasingly prominent. The Middle East, especially GCC markets, is adopting premium metabolic therapies amid high diabetes prevalence, advanced private care infrastructure, and growing interest in preventive cardiometabolic medicine. Africa remains earlier-stage for anti-obesity therapeutics, with access constrained by affordability, diagnostic gaps, medicine availability, and health system capacity, even as urbanization and noncommunicable disease burdens increase across the region.

Key Group Insights

The G7 represents the strongest clinical and commercial base for anti-obesity therapeutics because of advanced regulatory systems, specialist prescribing capacity, established pharmaceutical reimbursement channels, and high levels of cardiometabolic disease diagnosis. The European Union is pivotal for market access strategy, as pricing, reimbursement, and health technology assessment decisions influence uptake across member states and shape evidence requirements for long-term obesity pharmacotherapy, including durability, safety, comorbidity reduction, and budget impact management.

BRICS markets are strategically important because they combine large populations, rising obesity prevalence, expanding middle-class demand, and growing local manufacturing capabilities. ASEAN offers a developing opportunity through urbanization, diabetes prevention priorities, and increasing investment in private healthcare systems, while the GCC is characterized by high cardiometabolic disease burden, premium care adoption, and strong demand for advanced metabolic interventions. NATO is not a healthcare market bloc, but its member economies include many high-income systems where supply security, medicine resilience, regulatory coordination, and advanced clinical infrastructure influence therapeutic availability and continuity of care.

Key Country Insights

The United States is the global demand center for anti-obesity therapeutics, supported by regulatory approvals, broad prescriber awareness, employer health benefits, and high obesity prevalence; CDC data reported U.S. adult obesity prevalence at 40.3% during August 2021 to August 2023. Canada is progressing through public and private reimbursement debates and structured health technology evaluation, while Mexico and Brazil face substantial public health need linked to obesity, type 2 diabetes, cardiovascular disease risk, and changing dietary patterns.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are balancing strong clinical demand against budget impact, with Germany and the United Kingdom serving as influential evidence and access markets because of structured assessment processes and specialist clinical networks. France, Italy, and Spain continue to emphasize reimbursement discipline, prescriber guidance, and long-term value demonstration, while Russia remains shaped by local regulatory requirements, affordability considerations, and supply-chain factors.

China and India represent large-scale growth opportunities due to rising obesity rates, expanding diabetes burdens, and increasing investment in metabolic care, although affordability and broad access remain important constraints. Japan and South Korea emphasize metabolic risk management, aging-population health priorities, and clinical evidence standards, supporting measured adoption of obesity pharmacotherapy. Australia combines high disease awareness with structured reimbursement evaluation and established obesity, diabetes, and cardiovascular care pathways, making evidence quality and cost-effectiveness central to access decisions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence beyond weight loss, including cardiovascular outcomes, diabetes prevention, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, renal markers, mobility, and quality-of-life improvements. Payers increasingly require proof of durable benefit, adherence support, appropriate patient selection, and reduced obesity-related complications to justify broader coverage.

Companies should also invest in scalable manufacturing, cold-chain resilience, oral and longer-acting formulations, pharmacovigilance systems, equitable pricing models, and real-world evidence programs. Partnerships with primary care networks, endocrinologists, cardiologists, hepatologists, sleep specialists, digital health providers, and employers can improve diagnosis, treatment persistence, and outcomes in the anti-obesity therapeutics market. Responsible communication, patient education, and continuity-of-care models will be critical to maintaining trust as demand expands.

Research Methodology

This executive summary is based on verified public health, regulatory, and clinical evidence from sources such as the World Health Organization, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European Medicines Agency, national health authorities, and peer-reviewed clinical trial publications. Key evidence includes obesity prevalence trends, regulatory approvals, clinical efficacy data, safety findings, cardiometabolic outcomes, and health system access considerations.

The methodology combines secondary research, cross-validation of clinical and regulatory milestones, assessment of regional healthcare structures, and analysis of market access dynamics. Insights are synthesized to reflect current conditions in anti-obesity therapeutics, including GLP-1 receptor agonists, dual incretin agonists, emerging oral therapies, amylin-based approaches, and next-generation metabolic drug pipelines, while avoiding market sizing, market share, and forecasting claims.

Conclusion

Anti-obesity therapeutics are entering a pivotal phase as clinical efficacy, cardiometabolic outcome data, and patient demand converge. The sector is no longer defined only by weight reduction; it is increasingly linked to cardiovascular risk reduction, diabetes management, liver and sleep-related comorbidity care, health system efficiency, and long-term chronic disease management.

Sustained leadership will depend on evidence quality, manufacturing reliability, affordability, equitable access, safety monitoring, and the ability to integrate pharmacotherapy with digital care, nutrition, physical activity, and behavioral support. Organizations that demonstrate durable health outcomes, responsible commercialization, and patient-centered access are best positioned to shape the next decade of obesity treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-Obesity Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Prescription Drugs
7.2.1. GLP 1 Receptor Agonists
7.2.1.1. Semaglutide
7.2.1.2. Liraglutide
7.2.1.3. Tirzepatide
7.2.2. Combination Therapies
7.2.2.1. Phentermine Topiramate
7.2.2.2. Bupropion Naltrexone
7.2.3. Lipase Inhibitors
7.2.4. Sympathomimetic Agents
7.3. Over the Counter Drugs
8. Anti-Obesity Therapeutics Market, by Mechanism of Action
8.1. Introduction
8.2. Centrally Acting Drugs
8.2.1. Appetite Suppressants
8.2.2. Neurotransmitter Modulators
8.3. Peripherally Acting Drugs
8.3.1. Fat Absorption Blockers
8.3.2. Metabolic Enhancers
8.4. Hormonal Based Therapies
9. Anti-Obesity Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsules
9.2.2. Tablets
9.3. Injectable
9.3.1. Intramuscular
9.3.2. Subcutaneous
9.4. Transdermal
10. Anti-Obesity Therapeutics Market, by Indication
10.1. Introduction
10.2. Obesity
10.3. Overweight with Comorbidities
10.3.1. Type 2 Diabetes
10.3.2. Cardiovascular Diseases
10.3.3. Hypertension
10.3.4. Dyslipidemia
10.4. Genetic Obesity Disorders
10.5. Hypothalamic Obesity
11. Anti-Obesity Therapeutics Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Specialty Clinics
11.4. Weight Loss Centers
11.5. Homecare Settings
11.6. Ambulatory Surgical Centers
12. Anti-Obesity Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Anti-Obesity Therapeutics Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Anti-Obesity Therapeutics Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Anti-Obesity Therapeutics Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Aardvark Therapeutics
17.2. Altimmune, Inc.
17.3. Amgen Inc.
17.4. Antag Therapeutics ApS
17.5. Ascletis Pharma Inc.
17.6. AstraZeneca PLC
17.7. Boehringer Ingelheim International GmbH
17.8. Currax Pharmaceuticals LLC
17.9. Eli Lilly and Company
17.10. Hanmi Pharm. Co., Ltd.
17.11. Innovent Biologics, Inc.
17.12. Kailera Therapeutics
17.13. Metsera, Inc.
17.14. Novo Nordisk A/S
17.15. Pfizer Inc.
17.16. Rhythm Pharmaceuticals, Inc.
17.17. Roche Holding AG
17.18. Sciwind Biosciences
17.19. Structure Therapeutics Inc.
17.20. Sun Pharmaceutical Industries Ltd.
17.21. Takeda Pharmaceutical Company Limited
17.22. Teva Pharmaceutical Industries Ltd.
17.23. Viking Therapeutics, Inc.
17.24. Zealand Pharma A/S
17.25. Zydus Lifesciences Limited
18. Key Experts
List of Figures
FIGURE 1. Global Anti-Obesity Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Anti-Obesity Therapeutics Market, Research Design
FIGURE 3. Global Anti-Obesity Therapeutics Market, Research Framework
FIGURE 4. Global Anti-Obesity Therapeutics Market, Data Triangulation
FIGURE 5. Global Anti-Obesity Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Anti-Obesity Therapeutics Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Anti-Obesity Therapeutics Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2025 vs 2032 (%)
FIGURE 9. Global Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Anti-Obesity Therapeutics Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 13. Global Anti-Obesity Therapeutics Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Anti-Obesity Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Anti-Obesity Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Anti-Obesity Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Anti-Obesity Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Anti-Obesity Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Anti-Obesity Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Anti-Obesity Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Anti-Obesity Therapeutics Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Anti-Obesity Therapeutics Market Segmentation & Coverage
TABLE 2. Global Anti-Obesity Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Prescription Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Prescription Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Prescription Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global GLP 1 Receptor Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global GLP 1 Receptor Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global GLP 1 Receptor Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Semaglutide Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Semaglutide Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Semaglutide Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Liraglutide Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Liraglutide Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Liraglutide Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Tirzepatide Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Tirzepatide Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Tirzepatide Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Combination Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Combination Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Combination Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Phentermine Topiramate Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Phentermine Topiramate Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Phentermine Topiramate Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Bupropion Naltrexone Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Bupropion Naltrexone Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Bupropion Naltrexone Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Lipase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Lipase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Lipase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Sympathomimetic Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Sympathomimetic Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Sympathomimetic Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Over the Counter Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Over the Counter Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Over the Counter Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 38. Global Centrally Acting Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Centrally Acting Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Centrally Acting Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Appetite Suppressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Appetite Suppressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Appetite Suppressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Neurotransmitter Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Neurotransmitter Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Neurotransmitter Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Peripherally Acting Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Peripherally Acting Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Peripherally Acting Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Fat Absorption Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Fat Absorption Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Fat Absorption Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Metabolic Enhancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Metabolic Enhancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Metabolic Enhancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Hormonal Based Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Hormonal Based Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Hormonal Based Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 60. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 82. Global Obesity Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Obesity Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Obesity Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Overweight with Comorbidities Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Overweight with Comorbidities Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Overweight with Comorbidities Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Type 2 Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Type 2 Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Type 2 Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Hypertension Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Hypertension Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Hypertension Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Dyslipidemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Dyslipidemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Dyslipidemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Genetic Obesity Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Genetic Obesity Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Genetic Obesity Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Hypothalamic Obesity Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Hypothalamic Obesity Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Hypothalamic Obesity Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Weight Loss Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Weight Loss Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Weight Loss Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. North America Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. North America Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 147. North America Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 148. North America Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 149. North America Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 150. North America Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 151. North America Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 152. North America Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 153. North America Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. North America Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 155. North America Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 156. North America Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. North America Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 158. North America Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. North America Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Latin America Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Latin America Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 162. Latin America Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 163. Latin America Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 164. Latin America Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 165. Latin America Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 166. Latin America Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 167. Latin America Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 168. Latin America Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 169. Latin America Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 170. Latin America Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 171. Latin America Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. Latin America Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 173. Latin America Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. Latin America Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Europe Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 176. Europe Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 177. Europe Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 178. Europe Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 179. Europe Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 180. Europe Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 181. Europe Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 182. Europe Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 183. Europe Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 184. Europe Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 185. Europe Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 186. Europe Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. Europe Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 188. Europe Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. Europe Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Middle East Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Middle East Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 192. Middle East Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 193. Middle East Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 194. Middle East Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 195. Middle East Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 196. Middle East Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 197. Middle East Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 198. Middle East Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. Middle East Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 200. Middle East Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 201. Middle East Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. Middle East Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 203. Middle East Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. Middle East Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Africa Anti-Obesity Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Africa Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 207. Africa Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 208. Africa Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 209. Africa Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 210. Africa Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 211. Africa Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 212. Africa Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 213. Africa Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 214. Africa Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 215. Africa Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 216. Africa Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 217. Africa Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 218. Africa Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Africa Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Global Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. ASEAN Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. ASEAN Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 223. ASEAN Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 224. ASEAN Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 225. ASEAN Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 226. ASEAN Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 227. ASEAN Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 228. ASEAN Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 229. ASEAN Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 230. ASEAN Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 231. ASEAN Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 232. ASEAN Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. ASEAN Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 234. ASEAN Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. ASEAN Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. GCC Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. GCC Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 238. GCC Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 239. GCC Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 240. GCC Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 241. GCC Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 242. GCC Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 243. GCC Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 244. GCC Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 245. GCC Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 246. GCC Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 247. GCC Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. GCC Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 249. GCC Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. GCC Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. European Union Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. European Union Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 253. European Union Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 254. European Union Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 255. European Union Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 256. European Union Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 257. European Union Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 258. European Union Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 259. European Union Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. European Union Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 261. European Union Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 262. European Union Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 263. European Union Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 264. European Union Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. European Union Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. BRICS Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 267. BRICS Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 268. BRICS Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 269. BRICS Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 270. BRICS Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 271. BRICS Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 272. BRICS Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 273. BRICS Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 274. BRICS Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 275. BRICS Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 276. BRICS Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 277. BRICS Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. BRICS Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 279. BRICS Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. BRICS Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. G7 Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 282. G7 Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 283. G7 Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 284. G7 Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 285. G7 Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 286. G7 Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 287. G7 Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 288. G7 Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 289. G7 Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 290. G7 Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 291. G7 Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 292. G7 Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. G7 Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 294. G7 Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 295. G7 Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 296. NATO Anti-Obesity Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 297. NATO Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 298. NATO Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 299. NATO Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 300. NATO Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 301. NATO Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 302. NATO Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 303. NATO Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 304. NATO Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 305. NATO Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 306. NATO Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 307. NATO Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 308. NATO Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 309. NATO Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. NATO Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. Global Anti-Obesity Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 312. United States Anti-Obesity Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 313. United States Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 314. United States Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 315. United States Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 316. United States Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 317. United States Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 318. United States Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 319. United States Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 320. United States Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 321. United States Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 322. United States Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 323. United States Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 324. United States Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 325. United States Anti-Obesity Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 326. United States Anti-Obesity Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 327. Canada Anti-Obesity Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 328. Canada Anti-Obesity Therapeutics Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 329. Canada Anti-Obesity Therapeutics Market Size, by Prescription Drugs, 2017-2032 (USD Million)
TABLE 330. Canada Anti-Obesity Therapeutics Market Size, by GLP 1 Receptor Agonists, 2017-2032 (USD Million)
TABLE 331. Canada Anti-Obesity Therapeutics Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 332. Canada Anti-Obesity Therapeutics Market Size, by Mechanism of Action, 2017-2032 (USD Million)
TABLE 333. Canada Anti-Obesity Therapeutics Market Size, by Centrally Acting Drugs, 2017-2032 (USD Million)
TABLE 334. Canada Anti-Obesity Therapeutics Market Size, by Peripherally Acting Drugs, 2017-2032 (USD Million)
TABLE 335. Canada Anti-Obesity Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 336. Canada Anti-Obesity Therapeutics Market Size, by Oral, 2017-2032 (USD Million)
TABLE 337. Canada Anti-Obesity Therapeutics Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 338. Canada Anti-Obesity Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 339. Canada Anti-Obesity Therapeutics Market Size, by Overweight with Comorbidities, 2017-2032 (USD Million)
TABLE 340. Canada Anti-Obesity Therapeutics Marke

Companies Mentioned

  • Aardvark Therapeutics
  • Altimmune, Inc.
  • Amgen Inc.
  • Antag Therapeutics ApS
  • Ascletis Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Hanmi Pharm. Co., Ltd.
  • Innovent Biologics, Inc.
  • Kailera Therapeutics
  • Metsera, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sciwind Biosciences
  • Structure Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 12.67 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.21 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Anti-obesity Prescription Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-obesity Prescription Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Obesity Treatment Market - Global Forecast 2026-2032 - Product Image

Obesity Treatment Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Obesity - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Obesity - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Oral Obesity Therapies Market Report 2026 - Product Image

Oral Obesity Therapies Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Digital Health for Obesity - Global Strategic Business Report - Product Image

Digital Health for Obesity - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.